Interleukin 13 inhibitors - Pipeline Insight, 2024

Interleukin 13 inhibitors - Pipeline Insight, 2024

DelveInsight’s, “Interleukin-13 (IL-13) Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Interleukin-13 (IL-13) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Interleukin-13 (IL-13) Inhibitors Understanding

Interleukin-13 (IL-13) Inhibitors: Overview

IL-13 is an important cytokine in chronic airways inflammation. IL-13 is involved in Th2 inflammation and has been identified as a possible therapeutic target in the treatment of asthma and allergies. IL-13 gene encodes an immunoregulatory cytokine produced primarily by activated Th2 cells. This cytokine is involved in several stages of B-cell maturation and differentiation. It up-regulates CD23 and MHC class II expression, and promotes IgE isotype switching of B cells. This cytokine down-regulates macrophage activity, thereby inhibits the production of pro-inflammatory cytokines and chemokines.

Function – IL-13 is a 132-amino-acid nonglycosylated cytokine that shares common features with IL-4. IL-13 inhibits TNF, IL-1, IL-8, and MIP-1a production, NF-kB activation and CD14 and Fcg receptor expression. It induces cell surface expression of b2 integrins and MHC class II antigens. IL-13 appears to play a profibrotic role in the aging heart. Interleukin (IL)-13 is a cytokine that also represents a potential critical factor in the development and persistence of asthma.

Interleukin-13 (IL-13) Inhibitors- As interleukin (IL)-13 play a major role in various diseases including asthma, allergy, and malignancies, it is desirable to generate a molecule that blocks this cytokine. IL-13 inhibitor inhibits IL-4 binding to these cells and prevents heterodimer formation between IL-13Ralpha1 and IL-4Ralpha chains. This interference by IL-13 inhibitor blocks the biological activities of not only IL-13 but also partially of IL-4. Thus, IL-13 inhibitor may be a useful agent for the treatment of diseases such as asthma, allergic rhinitis, and cancer, which are dependent on signaling through both IL-4 and IL-13 receptors.

Interleukin-13 (IL-13) Inhibitors Emerging Drugs Chapters

This segment of the Interleukin-13 (IL-13) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Interleukin-13 (IL-13) Inhibitors Emerging Drugs

• Tralokinumab: Leo Pharma

Adtralza (tralokinumab) is a fully human, monoclonal antibody developed to specifically neutralize the IL-13 cytokine, which plays a key role in the immune process underlying atopic dermatitis signs and symptoms. Adtralza specifically binds to the IL-13 cytokine with high affinity, thereby preventing interaction with the IL-13 receptor α1 and α2 subunits. LEO Pharma Receives Positive CHMP Opinion of Adtralza (tralokinumab) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis.

• Dupilumab: Regeneron/Sabofi

Dupilumab was invented using Regeneron's proprietary VelocImmune® technology that utilizes a proprietary genetically-engineered mouse platform endowed with a genetically-humanized immune system to produce optimized fully-human antibodies. Regeneron and Sanofi are also studying dupilumab in a broad range of clinical development programs for diseases driven by allergic and other type 2 inflammation, including eosinophilic esophagitis (Phase 3), chronic obstructive pulmonary disease (Phase 3), bullous pemphigoid (Phase 3), prurigo nodularis (Phase 3), chronic spontaneous urticaria (Phase 3), and food and environmental allergies (Phase 2). Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement.

Further product details are provided in the report……..

Interleukin-13 (IL-13) Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Interleukin-13 (IL-13) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Interleukin-13 (IL-13) Inhibitors

There are approx. 10+ key companies which are developing the Interleukin-13 (IL-13) Inhibitors. The companies which have their Interleukin-13 (IL-13) Inhibitors drug candidates in the most advanced stage, i.e. preregistration include Leo pharma .

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III )
• Mid-stage products (Phase II )
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Interleukin-13 (IL-13) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intravenous
• Intramuscular
• Oral
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Interleukin-13 (IL-13) Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Interleukin-13 (IL-13) Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin-13 (IL-13) Inhibitors drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Interleukin-13 (IL-13) Inhibitors R&D.
• The therapies under development are focused on novel approaches for Interleukin-13 (IL-13) Inhibitors.

Interleukin-13 (IL-13) Inhibitors Report Insights

• Interleukin-13 (IL-13) Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Interleukin-13 (IL-13) Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Interleukin-13 (IL-13) Inhibitors drugs?
• How many Interleukin-13 (IL-13) Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Interleukin-13 (IL-13) Inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interleukin-13 (IL-13) Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Interleukin-13 (IL-13) Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?